A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Running, not enrolling · Phase 1 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Key facts

Study ID

NCT07225556

Run by

Eli Lilly and Company

People needed

84

Starts

2025-11-18

Expected to finish

2026-12-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant must be 21 for Singapore site
• Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
• Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent [%] body weight change)

You may not qualify if…

• Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
• Is an individual of childbearing potential (IOCBP)

Where it is running

• Fortrea Clinical Research Unit — Madison, Wisconsin, United States
• Lilly Centre for Clinical Pharmacology — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.